731 reports of this reaction
5.6% of all ELETRIPTAN HYDROBROMIDE reports
#3 most reported adverse reaction
HEADACHE is the #3 most commonly reported adverse reaction for ELETRIPTAN HYDROBROMIDE, manufactured by ROERIG. There are 731 FDA adverse event reports linking ELETRIPTAN HYDROBROMIDE to HEADACHE. This represents approximately 5.6% of all 13,057 adverse event reports for this drug.
Patients taking ELETRIPTAN HYDROBROMIDE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among ELETRIPTAN HYDROBROMIDE users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for ELETRIPTAN HYDROBROMIDE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 731 FDA reports for ELETRIPTAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 5.6% of all adverse event reports for ELETRIPTAN HYDROBROMIDE, making it one of the most commonly reported side effect.
If you experience headache while taking ELETRIPTAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.